Vir Biotechnology (VIR) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Vir Biotechnology (VIR) overview

Vir Biotechnology (VIR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 68.6m and operating profit of USD -479m; the year-end share price was 6.03 USD and market capitalisation was USD 841m. Vir Biotechnology is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Vir Biotechnology's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 765mFY 2025
Share price6.03 USDFY 2025 year end
RevenueUSD 68.6mFY 2025
Operating profitUSD -479mFY 2025
Net earningsUSD -438mFY 2025
Market capitalisationUSD 841mFY 2025 year end

About Vir Biotechnology

Vir Biotechnology discovers and develops antibody-based medicines and immunotherapies for serious infectious diseases and cancer. Its pipeline includes a Phase 3 combination therapy for chronic hepatitis delta and investigational T-cell engagers for solid tumors, alongside preclinical research. The company applies antibody engineering, AI-enabled protein design, and masking technology, and collaborates with pharmaceutical partners on clinical and preclinical development programs.

Generate the Vir Biotechnology report

Vir Biotechnology is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Vir Biotechnology and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Vir Biotechnology

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.